• 1

    JemalASiegelRXuJWardE. Cancer statistics, 2010. CA Cancer J Clin2010;60:277300.

  • 2

    GrovesFDLinetMSTravisLBDevesaSS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst2000;92:12401251.

    • Search Google Scholar
    • Export Citation
  • 3

    RappaportH. Tumors of the hematopoietic system. In: Atlas of Tumor Pathology Series (ed I). Washington, DC: Armed Forces Institute of Pathology; 1966.

    • Search Google Scholar
    • Export Citation
  • 4

    HicksEBRappaportHWinterWJ. Follicular lymphoma; a reevaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer1956;9:792821.

    • Search Google Scholar
    • Export Citation
  • 5

    BennettaMHFarrer-BrownGHenryK. Classification of non-Hodgkin’s lymphomas. Lancet1974;2:405408.

  • 6

    LennertK. Malignant lymphomas other than Hodgkin’s disease. New York: Springer-Verlag; 1978.

  • 7

    LennertKFellerA. Histopathology of non-Hodgkin’s lymphomas2nd ed.Berlin, Germany: Springer-Verlag; 1992.

  • 8

    National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer1982;49:21122135.

    • Search Google Scholar
    • Export Citation
  • 9

    Classification of non-Hodgkin’s lymphomas. Reproducibility of major classification systems. NCI non-Hodgkin’s Classification Project Writing Committee. Cancer1985;55:9195.

    • Search Google Scholar
    • Export Citation
  • 10

    HarrisNLJaffeESSteinH. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood1994;84:13611392.

    • Search Google Scholar
    • Export Citation
  • 11

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood1997;89:39093918.

    • Search Google Scholar
    • Export Citation
  • 12

    ArmitageJOWeisenburgerDD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol1998;16:27802795.

    • Search Google Scholar
    • Export Citation
  • 13

    HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 14

    JaffeESHarrisNLSteinHVardimanJW. WHO classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2001.

    • Search Google Scholar
    • Export Citation
  • 15

    VoseJArmitageJWeisenburgerD. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol2008;26:41244130.

    • Search Google Scholar
    • Export Citation
  • 16

    JaffeESHarrisNLSteinHIsaacsonPG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood2008;112:43844399.

    • Search Google Scholar
    • Export Citation
  • 17

    SwerdlowSHCampoEHarrisNL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008.

  • 18

    ChesonBDHorningSJCoiffierB. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol1999;17:12441253.

    • Search Google Scholar
    • Export Citation
  • 19

    ChesonBDPfistnerBJuweidME. Revised response criteria for malignant lymphoma. J Clin Oncol2007;25:579586.

  • 20

    HehnSTGroganTMMillerTP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol2004;22:30463052.

  • 21

    MedaBABussDHWoodruffRD. Diagnosis and subclassification of primary and recurrent lymphoma. The usefulness and limitations of combined fine-needle aspiration cytomorphology and flow cytometry. Am J Clin Pathol2000;113:688699.

    • Search Google Scholar
    • Export Citation
  • 22

    DongHYHarrisNLPrefferFIPitmanMB. Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry. Mod Pathol2001;14:472481.

    • Search Google Scholar
    • Export Citation
  • 23

    JeffersMDMiltonJHerriotRMcKeanM. Fine needle aspiration cytology in the investigation on non-Hodgkin’s lymphoma. J Clin Pathol1998;51:189196.

    • Search Google Scholar
    • Export Citation
  • 24

    ZeppaPMarinoGTronconeG. Fine-needle cytology and flow cytometry immunophenotyping and subclassification of non-Hodgkin lymphoma: a critical review of 307 cases with technical suggestions. Cancer2004;102:5565.

    • Search Google Scholar
    • Export Citation
  • 25

    DunphyCH. Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med2004;128:10041022.

    • Search Google Scholar
    • Export Citation
  • 26

    HowellSJShaletSM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep2002;4:443452.

    • Search Google Scholar
    • Export Citation
  • 27

    ConlanMGBastMArmitageJOWeisenburgerDD. Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol1990;8:11631172.

    • Search Google Scholar
    • Export Citation
  • 28

    LimSTTaoMCheungYB. Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?Ann Oncol2005;16:215218.

    • Search Google Scholar
    • Export Citation
  • 29

    KimYHWillemzeRPimpinelliN. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood2007;110:479484.

    • Search Google Scholar
    • Export Citation
  • 30

    SenffNKluin-NelemansHWillemzeR. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol2008;142:5256.

    • Search Google Scholar
    • Export Citation
  • 31

    JunejaSKWolfMMCooperIA. Value of bilateral bone marrow biopsy specimens in non-Hodgkin’s lymphoma. J Clin Pathol1990;43:630632.

  • 32

    SeamPJuweidMEChesonBD. The role of FDG-PET scans in patients with lymphoma. Blood2007;110:35073516.

  • 33

    IsasiCRLuPBlaufoxMD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer2005;104:10661074.

    • Search Google Scholar
    • Export Citation
  • 34

    TrotmanJFournierMLamyT. Result of FDG PET-CT imaging after immunochemotherapy induction is a powerful and independent prognostic indicator of outcome for patients with follicular lymphoma: an analysis from the PRIMA study [abstract]. Blood2010;116:Abstract 855.

    • Search Google Scholar
    • Export Citation
  • 35

    FeeneyJHorwitzSGonenMSchoderH. Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol2010;195:333340.

  • 36

    HoffmannMKletterKBechererA. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology2003;64:336340.

    • Search Google Scholar
    • Export Citation
  • 37

    Rodriguez-VigilBGomez-LeonNPinillaI. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med2006;47:16431648.

    • Search Google Scholar
    • Export Citation
  • 38

    SchaeferNGHanyTFTavernaC. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT?Radiology2004;232:823829.

    • Search Google Scholar
    • Export Citation
  • 39

    LauGK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int2008;2:152162.

  • 40

    LudwigEMendelsohnRBTaurY. Prevalence of hepatitis B surface antigen and hepatitis B core antibody in a population initiating immunosuppressive therapy [abstract]. J Clin Oncol2010;28:Abstract 9009.

    • Search Google Scholar
    • Export Citation
  • 41

    HwangJFischMZhangH. Hepatitis B screening and positivity prior to chemotherapy [abstract]. J Clin Oncol2010;28:Abstract 9008.

  • 42

    LokASLiangRHChiuEK. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology1991;100:182188.

    • Search Google Scholar
    • Export Citation
  • 43

    LalazarGRundDShouvalD. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol2007;136:699712.

    • Search Google Scholar
    • Export Citation
  • 44

    YeoWChanPKZhongS. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol2000;62:299307.

    • Search Google Scholar
    • Export Citation
  • 45

    TarghettaCCabrasMGMamusaAM. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica2008;93:951952.

    • Search Google Scholar
    • Export Citation
  • 46

    LoombaRRowleyAWesleyR. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med2008;148:519528.

    • Search Google Scholar
    • Export Citation
  • 47

    TsutsumiYKawamuraTSaitohS. Hepatitis B virus reactivation in a case of non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma2004;45:627629.

    • Search Google Scholar
    • Export Citation
  • 48

    TsutsumiYTanakaJKawamuraT. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann Hematol2004;83:5860.

    • Search Google Scholar
    • Export Citation
  • 49

    LauGKYiuHHFongDY. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology2003;125:17421749.

    • Search Google Scholar
    • Export Citation
  • 50

    CarsonKREvensAMRicheyEA. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood2009;113:48344840.

    • Search Google Scholar
    • Export Citation
  • 51

    CoiffierBAltmanAPuiCH. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol2008;26:27672778.

    • Search Google Scholar
    • Export Citation
  • 52

    CairoMSBishopM. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol2004;127:311.

  • 53

    KrakoffIHMeyerRL. Prevention of hyperuricemia in leukemia and lymphoma: use of alopurinol, a xanthine oxidase inhibitor. JAMA1965;193:16.

    • Search Google Scholar
    • Export Citation
  • 54

    BoslyASonetAPinkertonCR. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer2003;98:10481054.

    • Search Google Scholar
    • Export Citation
  • 55

    CoiffierBMounierNBolognaS. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol2003;21:44024406.

    • Search Google Scholar
    • Export Citation
  • 56

    CortesJMooreJOMaziarzRT. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone-results of a multicenter phase III study. J Clin Oncol2010;28:42074213.

    • Search Google Scholar
    • Export Citation
  • 57

    TsimberidouAMWenSO’BrienS. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol2007;25:46484656.

    • Search Google Scholar
    • Export Citation
  • 58

    DohnerHStilgenbauerSBennerA. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med2000;343:19101916.

  • 59

    NeilsonJRAuerRWhiteD. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia1997;11:19291932.

    • Search Google Scholar
    • Export Citation
  • 60

    AustenBSkowronskaABakerC. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol2007;25:54485457.

    • Search Google Scholar
    • Export Citation
  • 61

    TsimberidouAMTamCAbruzzoLV. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer2009;115:373380.

    • Search Google Scholar
    • Export Citation
  • 62

    RossiDCerriMDeambrogiC. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res2009;15:9951004.

    • Search Google Scholar
    • Export Citation
  • 63

    ZenzTMohrJEdelmannJ. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway. Leuk Lymphoma2009;50:510513.

    • Search Google Scholar
    • Export Citation
  • 64

    TamCSShanafeltTDWierdaWG. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood2009;114:957964.

    • Search Google Scholar
    • Export Citation
  • 65

    ZenzTKroberASchererK. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood2008;112:33223329.

    • Search Google Scholar
    • Export Citation
  • 66

    ZenzTEichhorstBBuschR. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol2010;28:44734479.

  • 67

    ZenzTHothPBuschR. TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG [abstract]. Blood2009;114:Abstract 1267.

    • Search Google Scholar
    • Export Citation
  • 68

    ByrdJCGribbenJGPetersonBL. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol2006;24:437443.

    • Search Google Scholar
    • Export Citation
  • 69

    GreverMRLucasDMDewaldGW. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup phase III trial E2997. J Clin Oncol2007;25:799804.

    • Search Google Scholar
    • Export Citation
  • 70

    CatovskyDRichardsSMatutesE. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet2007;370:230239.

    • Search Google Scholar
    • Export Citation
  • 71

    MorenoCMontserratE. New prognostic markers in chronic lymphocytic leukemia. Blood Rev2008;22:211219.

  • 72

    TsimberidouAMTamCWierdaW. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [abstract]. J Clin Oncol2007;25:Abstract 7034.

    • Search Google Scholar
    • Export Citation
  • 73

    HamblinTJDavisZGardinerA. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood1999;94:18481854.

    • Search Google Scholar
    • Export Citation
  • 74

    HamblinTJDavisZAOscierDG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia—long-term follow up of patients with different percentages of mutations. Br J Haematol2008;140:320323.

    • Search Google Scholar
    • Export Citation
  • 75

    TobinGThunbergUJohnsonA. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood2002;99:22622264.

    • Search Google Scholar
    • Export Citation
  • 76

    GhiaPGuidaGStellaS. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood2003;101:12621269.

    • Search Google Scholar
    • Export Citation
  • 77

    DamleRNWasilTFaisF. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999;94:18401847.

    • Search Google Scholar
    • Export Citation
  • 78

    ThorntonPDFernandezCGiustolisiGM. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J2004;5:145151.

    • Search Google Scholar
    • Export Citation
  • 79

    Del PrincipeMIDel PoetaGBuccisanoF. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood2006;108:853861.

    • Search Google Scholar
    • Export Citation
  • 80

    RassentiLZHuynhLToyTL. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med2004;351:893901.

    • Search Google Scholar
    • Export Citation
  • 81

    WiestnerARosenwaldABarryTS. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood2003;101:49444951.

    • Search Google Scholar
    • Export Citation
  • 82

    CrespoMBoschFVillamorN. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med2003;348:17641775.

    • Search Google Scholar
    • Export Citation
  • 83

    D’ArenaGTarnaniMRumiC. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol2007;82:787791.

    • Search Google Scholar
    • Export Citation
  • 84

    Del GiudiceIMorillaAOsujiN. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer2005;104:21242132.

    • Search Google Scholar
    • Export Citation
  • 85

    MorillaAGonzalez de CastroDDel GiudiceI. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma2008;49:21082115.

    • Search Google Scholar
    • Export Citation
  • 86

    SchroersRGriesingerFTrumperL. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia2005;19:750758.

    • Search Google Scholar
    • Export Citation
  • 87

    WierdaWO’BrienSWangX. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood2007;109:46794685.

    • Search Google Scholar
    • Export Citation
  • 88

    RaiKRSawitskyACronkiteEP. Clinical staging of chronic lymphocytic leukemia. Blood1975;46:219234.

  • 89

    BinetJAuquierADighieroG. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer1981;48:198206.

    • Search Google Scholar
    • Export Citation
  • 90

    RawstronAC. Monoclonal B-cell lymphocytosis. Hematology Am Soc Hematol Educ Program2009:430439.

  • 91

    RawstronACBennettFLO’ConnorSJ. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med2008;359:575583.

  • 92

    DickerFSchnittgerSHaferlachT. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood2006;108:31523160.

    • Search Google Scholar
    • Export Citation
  • 93

    PutNKoningsPRackK. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer2009;48:843853.

    • Search Google Scholar
    • Export Citation
  • 94

    StruskiSGervaisCHeliasC. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia2009;23:617619.

    • Search Google Scholar
    • Export Citation
  • 95

    HeeremaNAByrdJCCinPD. Karyotype results from CpG oligodeoxynucleotide stimulated chronic lymphocytic leukemia (CLL) cultures are consistent among laboratories: a CLL Research Consortium (CRC) study [abstract]. Blood2009;114:Abstract 1614.

    • Search Google Scholar
    • Export Citation
  • 96

    ChesonBDBennettJMGreverM. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood1996;87:49904997.

    • Search Google Scholar
    • Export Citation
  • 97

    HallekMChesonBDCatovskyD. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood2008;111:54465456.

    • Search Google Scholar
    • Export Citation
  • 98

    RaphaelBAndersenJWSilberR. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol1991;9:770776.

    • Search Google Scholar
    • Export Citation
  • 99

    RaiKRPetersonBLAppelbaumFR. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med2000;343:17501757.

    • Search Google Scholar
    • Export Citation
  • 100

    EichhorstBGoedeVHallekM. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma2009;50:171178.

  • 101

    LeporrierMChevretSCazinB. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood2001;98:23192325.

    • Search Google Scholar
    • Export Citation
  • 102

    FlinnIWNeubergDSGreverMR. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol2007;25:793798.

    • Search Google Scholar
    • Export Citation
  • 103

    EichhorstBFBuschRHopfingerG. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood2006;107:885891.

    • Search Google Scholar
    • Export Citation
  • 104

    ByrdJCPetersonBLMorrisonVA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood2003;101:614.

    • Search Google Scholar
    • Export Citation
  • 105

    WoyachJARuppertASHeeremaNA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB Study 9712. J Clin Oncol2011;29:13491355.

    • Search Google Scholar
    • Export Citation
  • 106

    ByrdJCRaiKPetersonBL. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood2005;105:4953.

    • Search Google Scholar
    • Export Citation
  • 107

    KeatingMJO’BrienSAlbitarM. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol2005;23:40794088.

    • Search Google Scholar
    • Export Citation
  • 108

    TamCSO’BrienSWierdaW. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood2008;112:975980.

    • Search Google Scholar
    • Export Citation
  • 109

    ParikhSAWierdaWGBadouxX. Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol2010;28(Suppl 1):Abstract 6519.

    • Search Google Scholar
    • Export Citation
  • 110

    HallekMFischerKFingerle-RowsonG. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet2010;376:11641174.

    • Search Google Scholar
    • Export Citation
  • 111

    KayNEGeyerSMCallTG. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood2007;109:405411.

    • Search Google Scholar
    • Export Citation
  • 112

    KayNEWuWKabatB. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer2010;116:21802187.

    • Search Google Scholar
    • Export Citation
  • 113

    KnaufWULissichkovTAldaoudA. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol2009;27:43784384.

    • Search Google Scholar
    • Export Citation
  • 114

    KnaufWULissitchkovTAldaoudA. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia [abstract]. Blood2010;116:Abstract 2449.

    • Search Google Scholar
    • Export Citation
  • 115

    FischerKCramerPStilgenbauerS. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract]. Blood2009;114:Abstract 205.

    • Search Google Scholar
    • Export Citation
  • 116

    LundinJKimbyEBjorkholmM. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood2002;100:768773.

    • Search Google Scholar
    • Export Citation
  • 117

    HillmenPSkotnickiABRobakT. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol2007;25:56165623.

    • Search Google Scholar
    • Export Citation
  • 118

    WierdaWO’BrienSWenS. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol2005;23:40704078.

    • Search Google Scholar
    • Export Citation
  • 119

    RobakTDmoszynskaASolal-CelignyP. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol2010;28:17561765.

    • Search Google Scholar
    • Export Citation
  • 120

    LamannaNKalaycioMMaslakP. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol2006;24:15751581.

    • Search Google Scholar
    • Export Citation
  • 121

    WeissMAMaslakPGJurcicJG. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol2003;21:12781284.

    • Search Google Scholar
    • Export Citation
  • 122

    TsimberidouAMWierdaWGPlunkettW. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol2008;26:196203.

    • Search Google Scholar
    • Export Citation
  • 123

    TsimberidouAMWierdaWGWenS. Results of a phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) combination therapy in patients with aggressive, relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome (RS) [abstract]. Blood2010;116:Abstract 923.

    • Search Google Scholar
    • Export Citation
  • 124

    FischerKStilgenbauerSSchweighoferCD. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [abstract]. Blood2008;112:Abstract 330.

    • Search Google Scholar
    • Export Citation
  • 125

    BowenDACallTGJenkinsGD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma2007;48:24122417.

    • Search Google Scholar
    • Export Citation
  • 126

    CastroJEJamesDFSandoval-SusJD. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia2009;23:17791789.

    • Search Google Scholar
    • Export Citation
  • 127

    DungarwallaMEvansSORileyU. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica2008;93:475476.

    • Search Google Scholar
    • Export Citation
  • 128

    KeatingMJFlinnIJainV. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood2002;99:35543561.

    • Search Google Scholar
    • Export Citation
  • 129

    StilgenbauerSDohnerH. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med2002;347:452453.

    • Search Google Scholar
    • Export Citation
  • 130

    LozanskiGHeeremaNAFlinnIW. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood2004;103:32783281.

    • Search Google Scholar
    • Export Citation
  • 131

    OsujiNCDel GiudiceIMatutesE. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica2005;90:14351436.

    • Search Google Scholar
    • Export Citation
  • 132

    CortelezziAPasquiniMCSarinaB. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematologica2005;90:410412.

    • Search Google Scholar
    • Export Citation
  • 133

    KarlssonCLundinJKimbyE. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol2009;144:7885.

    • Search Google Scholar
    • Export Citation
  • 134

    StilgenbauerSZenzTWinklerD. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol2009;27:39944001.

    • Search Google Scholar
    • Export Citation
  • 135

    VargheseAMSayalaHAMoretonP. Long term survival report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group) [abstract]. Blood2010;116:Abstract 922.

    • Search Google Scholar
    • Export Citation
  • 136

    FieglMErdelMTinhoferI. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol2010;21:24102419.

    • Search Google Scholar
    • Export Citation
  • 137

    ElterTBorchmannPSchulzH. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol2005;23:70247031.

    • Search Google Scholar
    • Export Citation
  • 138

    KennedyBRawstronACarterC. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood2002;99:22452247.

    • Search Google Scholar
    • Export Citation
  • 139

    FaderlSThomasDAO’BrienS. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood2003;101:34133415.

    • Search Google Scholar
    • Export Citation
  • 140

    NabhanCPattonDGordonL. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma2004;45:22692273.

    • Search Google Scholar
    • Export Citation
  • 141

    BadouxXCKeatingMO’BrienS. Chemoimmunotherapy with cyclophosphomide, fludarabine, alemtuzumab and rituximab (cfar) is effective in relapsed patients with chronic lymphocytic leukemia (CLL) [abstract]. Blood2009;114:Abstract 3431.

    • Search Google Scholar
    • Export Citation
  • 142

    CoiffierBLepretreSPedersenLM. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood2008;111:10941100.

    • Search Google Scholar
    • Export Citation
  • 143

    WierdaWGKippsTJMayerJ. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol2010;28:17491755.

    • Search Google Scholar
    • Export Citation
  • 144

    WierdaWGKippsTJMayerJ. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood2010;116:Abstract 921.

    • Search Google Scholar
    • Export Citation
  • 145

    GribbenJGZahriehDStephansK. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood2005;106:43894396.

    • Search Google Scholar
    • Export Citation
  • 146

    KhouriIFKeatingMJSalibaRMChamplinRE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy2002;4:217221.

    • Search Google Scholar
    • Export Citation
  • 147

    SorrorMLStorerBESandmaierBM. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol2008;26:49124920.

    • Search Google Scholar
    • Export Citation
  • 148

    KhouriIFSalibaRMAdmirandJ. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol2007;137:355363.

    • Search Google Scholar
    • Export Citation
  • 149

    MorenoCVillamorNColomerD. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol2005;23:34333438.

    • Search Google Scholar
    • Export Citation
  • 150

    ScheteligJvan BiezenABrandR. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol2008;26:50945100.

    • Search Google Scholar
    • Export Citation
  • 151

    DregerPStilgenbauerSBoettcherS. Prognostic factors for outcome of nonmyeloablative allogeneic stem cell transplantation (NST) in poor-risk chronic lymphocytic leukemia (CLL): final results from a prospective multicenter trial (GCLLSG CLL3X study) [abstract]. Blood2008;112:Abstract 565.

    • Search Google Scholar
    • Export Citation
  • 152

    TsimberidouAMKeatingMJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer2009;115:28242836.

  • 153

    SalviFMillerMDGrilliA. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc2008;56:19261931.

    • Search Google Scholar
    • Export Citation
  • 154

    ReynoldsCDi BellaNLyonsRM. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Blood2008;112:Abstract 327.

    • Search Google Scholar
    • Export Citation
  • 155

    KeatingMJWierdaWGTamCS. Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia [abstract]. Blood2009;114:Abstract 2381.

    • Search Google Scholar
    • Export Citation
  • 156

    RossiDGaidanoG. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol2009;27:110.

  • 157

    TsimberidouAMKeatingMJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer2005;103:216228.

  • 158

    TsimberidouAMO’BrienSKantarjianHM. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer2006;107:12941302.

    • Search Google Scholar
    • Export Citation
  • 159

    TsimberidouAMO’BrienSKhouriI. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol2006;24:23432351.

    • Search Google Scholar
    • Export Citation
  • 160

    RodriguezJKeatingMJO’BrienS. Allogeneic haematopoietic transplantation for Richter’s syndrome. Br J Haematol2000;110:897899.

  • 161

    TsimberidouAMKantarjianHMCortesJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer2003;97:17111720.

    • Search Google Scholar
    • Export Citation
  • 162

    MorrisonVA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol2010;23:145153.

    • Search Google Scholar
    • Export Citation
  • 163

    TsaiHTCaporasoNEKyleRA. Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. Blood2009;114:49284932.

    • Search Google Scholar
    • Export Citation
  • 164

    PerkinsJGFlynnJMHowardRSByrdJC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer2002;94:20332039.

    • Search Google Scholar
    • Export Citation
  • 165

    ChapelHDicatoMGammH. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol1994;88:209212.

    • Search Google Scholar
    • Export Citation
  • 166

    Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med1988;319:902907.

    • Search Google Scholar
    • Export Citation
  • 167

    BoughtonBJJacksonNLimSSmithN. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol1995;17:7580.

    • Search Google Scholar
    • Export Citation
  • 168

    MolicaSMustoPChiurazziF. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica1996;81:121126.

    • Search Google Scholar
    • Export Citation
  • 169

    RaananiPGafter-GviliAPaulM. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma2009;50:764772.

    • Search Google Scholar
    • Export Citation
  • 170

    SinisaloMVilpoJItalaM. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine2007;26:8287.

    • Search Google Scholar
    • Export Citation
  • 171

    SinisaloMAittoniemiJKayhtyHVilpoJ. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma2003;44:649652.

  • 172

    Van der VeldenAMVan Velzen-BladHClaessenAM. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. Eur J Haematol2007;79:4752.

    • Search Google Scholar
    • Export Citation
  • 173

    JurlanderJde Nully BrownPSkovPS. Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia. Leukemia1995;9:19021909.

    • Search Google Scholar
    • Export Citation
  • 174

    NguyenDDCaoTMDuganK. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma2002;3:105110.

    • Search Google Scholar
    • Export Citation
  • 175

    LaurentiLPiccioniPCattaniP. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica2004;89:12481252.

    • Search Google Scholar
    • Export Citation
  • 176

    VisaniGMeleAGuiducciB. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. Leuk Lymphoma2006;47:25422546.

    • Search Google Scholar
    • Export Citation
  • 177

    O’BrienSMKeatingMJMocarskiES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma2006;7:125130.

    • Search Google Scholar
    • Export Citation
  • 178

    DeardenC. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program2008;2008:450456.

  • 179

    DingWZentCS. Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Adv Hematol Oncol2007;5:257261.

    • Search Google Scholar
    • Export Citation
  • 180

    BorthakurGO’BrienSWierdaWG. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab—incidence and predictors. Br J Haematol2007;136:800805.

    • Search Google Scholar
    • Export Citation
  • 181

    BarcelliniWCapalboSAgostinelliR. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica2006;91:16891692.

    • Search Google Scholar
    • Export Citation
  • 182

    ZanottiRFrattiniFGhiaP. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Am J Hematol2010;85:494498.

    • Search Google Scholar
    • Export Citation
  • 183

    MorenoCHodgsonKFerrerG. Autoimmune cytopenias in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood2010;116:47714776.

    • Search Google Scholar
    • Export Citation
  • 184

    ViscoCRuggeriMLaura EvangelistaM. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood2008;111:11101116.

    • Search Google Scholar
    • Export Citation
  • 185

    CortesJO’BrienSLoscertalesJ. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer2001;92:20162022.

    • Search Google Scholar
    • Export Citation
  • 186

    D’ArenaGLaurentiLCapalboS. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol2006;81:598602.

    • Search Google Scholar
    • Export Citation
  • 187

    GuptaNKavuruSPatelD. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia2002;16:20922095.

    • Search Google Scholar
    • Export Citation
  • 188

    BerentsenS. Rituximab for the treatment of autoimmune cytopenias. Haematologica2007;92:15891596.

  • 189

    GodeauBPorcherRFainO. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood2008;112:9991004.

    • Search Google Scholar
    • Export Citation
  • 190

    HegdeUPWilsonWHWhiteTChesonBD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood2002;100:22602262.

    • Search Google Scholar
    • Export Citation
  • 191

    ShanafeltTDMaduemeHLWolfRCTefferiA. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc2003;78:13401346.

    • Search Google Scholar
    • Export Citation
  • 192

    GhazalH. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood2002;99:10921094.

    • Search Google Scholar
    • Export Citation
  • 193

    BusselJBKuterDJNewlandA. Long-term efficacy and safety of romiplostim for the treatment of patients with chronic immune thrombocytopenia (ITP): 5-year update from an open-label extension study [abstract]. Blood2009;114:Abstract 681.

    • Search Google Scholar
    • Export Citation
  • 194

    KuterDJBusselJBLyonsRM. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet2008;371:395403.

    • Search Google Scholar
    • Export Citation
  • 195

    BusselJBChengGSalehMN. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med2007;357:22372247.

  • 196

    DeardenCWadeRElseM. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood2008;111:18201826.

    • Search Google Scholar
    • Export Citation
  • 197

    KosterATrompHARaemaekersJM. The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. Haematologica2007;92:184190.

    • Search Google Scholar
    • Export Citation
  • 198

    WangSAWangLHochbergEP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol2005;29:14901496.

    • Search Google Scholar
    • Export Citation
  • 199

    HansCPWeisenburgerDDVoseJM. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood2003;101:23632367.

    • Search Google Scholar
    • Export Citation
  • 200

    KatzenbergerTOttGKleinT. Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. Am J Pathol2004;165:481490.

    • Search Google Scholar
    • Export Citation
  • 201

    Solal-CelignyPRoyPColombatP. Follicular lymphoma international prognostic index. Blood2004;104:12581265.

  • 202

    FriedbergJWTaylorMDCerhanJR. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol2009;27:12021208.

    • Search Google Scholar
    • Export Citation
  • 203

    FedericoMBelleiMMarcheselliL. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol2009;27:45554562.

    • Search Google Scholar
    • Export Citation
  • 204

    SchoderHNoyAGonenM. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol2005;23:46434651.

    • Search Google Scholar
    • Export Citation
  • 205

    AdvaniRRosenbergSAHorningSJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol2004;22:14541459.

    • Search Google Scholar
    • Export Citation
  • 206

    McLaughlinPFullerLRedmanJ. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol1991;2(Suppl 2):137140.

    • Search Google Scholar
    • Export Citation
  • 207

    YahalomJVarsosGFuksZ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer1993;71:23422350.

    • Search Google Scholar
    • Export Citation
  • 208

    ColombatPSallesGBrousseN. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood2001;97:101106.

    • Search Google Scholar
    • Export Citation
  • 209

    WitzigTEVukovAMHabermannTM. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol2005;23:11031108.

    • Search Google Scholar
    • Export Citation
  • 210

    McLaughlinPGrillo-LopezAJLinkBK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol1998;16:28252833.

    • Search Google Scholar
    • Export Citation
  • 211

    SchulzHBohliusJFTrelleS. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst2007;99:706714.

    • Search Google Scholar
    • Export Citation
  • 212

    CzuczmanMSGrillo-LopezAJWhiteCA. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol1999;17:268276.

    • Search Google Scholar
    • Export Citation
  • 213

    CzuczmanMSWeaverRAlkuzwenyB. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol2004;22:47114716.

    • Search Google Scholar
    • Export Citation
  • 214

    HiddemannWKnebaMDreylingM. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood2005;106:37253732.

    • Search Google Scholar
    • Export Citation
  • 215

    BuskeCKnebaMLengfelderE. Front-line combined immuno-chemotherapy (R-CHOP) significantly improves the time to treatment failure and overall survival in elderly patients with advanced stage follicular lymphoma—results of a prospective randomized trial of the german low grade lymphoma study group (GLSG) [abstract]. Blood2006;108:Abstract 482.

    • Search Google Scholar
    • Export Citation
  • 216

    MarcusRImrieKBelchA. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood2005;105:14171423.

    • Search Google Scholar
    • Export Citation
  • 217

    MarcusRImrieKSolal-CelignyP. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol2008;26:45794586.

    • Search Google Scholar
    • Export Citation
  • 218

    CzuczmanMSKoryznaAMohrA. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol2005;23:694704.

    • Search Google Scholar
    • Export Citation
  • 219

    ForstpointnerRDreylingMReppR. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood2004;104:30643071.

    • Search Google Scholar
    • Export Citation
  • 220

    McLaughlinPHagemeisterFBRodriguezMA. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol2000;27:3741.

    • Search Google Scholar
    • Export Citation
  • 221

    ZinzaniPLPulsoniAPerrottiA. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol2004;22:26542661.

    • Search Google Scholar
    • Export Citation
  • 222

    RummelMJNiederleNMaschmeyerG. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood2009;114:Abstract 405.

    • Search Google Scholar
    • Export Citation
  • 223

    FriedbergJWCohenPChenL. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol2008;26:204210.

    • Search Google Scholar
    • Export Citation
  • 224

    KahlBSBartlettNLLeonardJP. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer2010;116:106114.

    • Search Google Scholar
    • Export Citation
  • 225

    RobinsonKSWilliamsMEvan der JagtRH. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol2008;26:44734479.

    • Search Google Scholar
    • Export Citation
  • 226

    RummelMJKaiserUBalserC. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL 2-2003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood2010;116:Abstract 856.

    • Search Google Scholar
    • Export Citation
  • 227

    KaminskiMSTuckMEstesJ. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med2005;352:441449.

  • 228

    VoseJMWahlRLSalehM. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol2000;18:13161323.

    • Search Google Scholar
    • Export Citation
  • 229

    KaminskiMSZelenetzADPressOW. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol2001;19:39183928.

    • Search Google Scholar
    • Export Citation
  • 230

    HorningSJYounesAJainV. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol2005;23:712719.

    • Search Google Scholar
    • Export Citation
  • 231

    WitzigTEFlinnIWGordonLI. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol2002;20:32623269.

    • Search Google Scholar
    • Export Citation
  • 232

    WitzigTEGordonLICabanillasF. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol2002;20:24532463.

    • Search Google Scholar
    • Export Citation
  • 233

    GordonLIWitzigTMolinaA. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma2004;5:98101.

    • Search Google Scholar
    • Export Citation
  • 234

    KaminskiMSTuckMEstesJ. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results [abstract]. Blood2009;114:Abstract 3759.

    • Search Google Scholar
    • Export Citation
  • 235

    ScholzCWPintoALinkeschW. 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. First results from an international phase II clinical trial [abstract]. Blood2010;116:Abstract 593.

    • Search Google Scholar
    • Export Citation
  • 236

    KaminskiMSZelenetzADPressOW. Tositumomab and I 131 tositumomab achieves complete remissions lasting > 10 years in patients with chemotherapy-refractory low-grade and transformed B-cell lymphomas [abstract]. Blood2010;116:Abstract 3960.

    • Search Google Scholar
    • Export Citation
  • 237

    YoungRCLongoDLGlatsteinE. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol1988;25:1116.

    • Search Google Scholar
    • Export Citation
  • 238

    BricePBastionYLepageE. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol1997;15:11101117.

    • Search Google Scholar
    • Export Citation
  • 239

    ArdeshnaKMSmithPNortonA. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet2003;362:516522.

    • Search Google Scholar
    • Export Citation
  • 240

    ArdeshnaKMQianWSmithP. An Intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood2010;116:Abstract 6.

    • Search Google Scholar
    • Export Citation
  • 241

    PetersonBAPetroniGRFrizzeraG. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol2003;21:515.

    • Search Google Scholar
    • Export Citation
  • 242

    LeonardJPColemanMKostakogluL. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol2005;23:56965704.

    • Search Google Scholar
    • Export Citation
  • 243

    PressOWUngerJMBrazielRM. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol2006;24:41434149.

    • Search Google Scholar
    • Export Citation
  • 244

    PressOWUngerJMBrazielRM. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911. Blood2003;102:16061612.

    • Search Google Scholar
    • Export Citation
  • 245

    LinkBKMartinPKaminskiMS. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol2010;28:30353041.

    • Search Google Scholar
    • Export Citation
  • 246

    HainsworthJDSpigelDRMarkusTM. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma2009;9:223228.

    • Search Google Scholar
    • Export Citation
  • 247

    JacobsSASwerdlowSHKantJ. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res2008;14:70887094.

    • Search Google Scholar
    • Export Citation
  • 248

    MorschhauserFRadfordJVan HoofA. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol2008;26:51565164.

    • Search Google Scholar
    • Export Citation
  • 249

    ZinzaniPLTaniMPulsoniA. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol2008;9:352358.

    • Search Google Scholar
    • Export Citation
  • 250

    HagenbeekARadfordJVan HoofA. 90Y-ibritumomab tiuxetan (Zevalin(R)) consolidation of first remission in advanced-stage follicular non-hodgkin’s lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized, phase III First-Line Indolent Trial (FIT) in 414 patients [abstract]. Blood2010;116:Abstract 594.

    • Search Google Scholar
    • Export Citation
  • 251

    GhielminiMSchmitzSFCogliattiSB. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood2004;103:44164423.

    • Search Google Scholar
    • Export Citation
  • 252

    MartinelliGHsu SchmitzSFUtigerU. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol2010;28:44804484.

    • Search Google Scholar
    • Export Citation
  • 253

    TavernaCJBassiSHitzF. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03 [abstract]. Blood2010;116:Abstract 1802.

    • Search Google Scholar
    • Export Citation
  • 254

    HainsworthJDLitchySShafferDW. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin’s lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol2005;23:10881095.

    • Search Google Scholar
    • Export Citation
  • 255

    HochsterHWellerEGascoyneRD. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol2009;27:16071614.

    • Search Google Scholar
    • Export Citation
  • 256

    SallesGASeymourJFFeugierP. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy [abstract]. J Clin Oncol2010;28:Abstract 8004.

    • Search Google Scholar
    • Export Citation
  • 257

    SallesGSeymourJFOffnerF. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet2011;377:4251.

    • Search Google Scholar
    • Export Citation
  • 258

    ForstpointnerRUnterhaltMDreylingM. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood2006;108:40034008.

    • Search Google Scholar
    • Export Citation
  • 259

    van OersMHKlasaRMarcusRE. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood2006;108:32953301.

    • Search Google Scholar
    • Export Citation
  • 260

    van OersMHVan GlabbekeMGiurgeaL. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol2010;28:28532858.

    • Search Google Scholar
    • Export Citation
  • 261

    FreedmanASNeubergDMauchP. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood1999;94:33253333.

    • Search Google Scholar
    • Export Citation
  • 262

    RohatinerAZNadlerLDaviesAJ. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol2007;25:25542559.

    • Search Google Scholar
    • Export Citation
  • 263

    SchoutenHCQianWKvaloyS. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol2003;21:39183927.

    • Search Google Scholar
    • Export Citation
  • 264

    SebbanCBricePDelarueR. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol2008;26:36143620.

    • Search Google Scholar
    • Export Citation
  • 265

    PeniketAJRuiz de ElviraMCTaghipourG. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant2003;31:667678.

    • Search Google Scholar
    • Export Citation
  • 266

    van BesienKLoberizaFRBajorunaiteR. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood2003;102:35213529.

    • Search Google Scholar
    • Export Citation
  • 267

    HariPCarrerasJZhangMJ. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant2008;14:236245.

    • Search Google Scholar
    • Export Citation
  • 268

    Al-TourahAJChhanabhaiMHoskinsPJ. Transformed lymphoma: incidence and long-term outcome [abstract]. Blood2004;104:Abstract 3253.

  • 269

    YuenARKamelOWHalpernJHorningSJ. Long-term survival after histologic transformation of low-grade follicular lymphoma. J Clin Oncol1995;13:17261733.

    • Search Google Scholar
    • Export Citation
  • 270

    AlizadehAAEisenMBDavisRE. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature2000;403:503511.

    • Search Google Scholar
    • Export Citation
  • 271

    HansCPWeisenburgerDDGreinerTC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood2004;103:275282.

    • Search Google Scholar
    • Export Citation
  • 272

    ChoiWWLWeisenburgerDDGreinerTC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res2009;15:54945502.

    • Search Google Scholar
    • Export Citation
  • 273

    A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med1993;329:987994.

    • Search Google Scholar
    • Export Citation
  • 274

    MillerTPDahlbergSCassadyJR. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med1998;339:2126.

    • Search Google Scholar
    • Export Citation
  • 275

    ShenkierTNVossNFaireyR. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol2002;20:197204.

    • Search Google Scholar
    • Export Citation
  • 276

    HorningSJWellerEKimK. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol2004;22:30323038.

    • Search Google Scholar
    • Export Citation
  • 277

    BonnetCFilletGMounierN. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol2007;25:787792.

    • Search Google Scholar
    • Export Citation
  • 278

    PerskyDOUngerJMSpierCM. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol2008;26:22582263.

    • Search Google Scholar
    • Export Citation
  • 279

    ReyesFLepageEGanemG. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med2005;352:11971205.

  • 280

    RecherCCoiffierBHaiounC. A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs standard R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL). Groupe d’Etude Des Lymphomes De l’Adulte (GELA) study LNH03-2B [abstract]. Blood2010;116:Abstract 109.

    • Search Google Scholar
    • Export Citation
  • 281

    FisherRIGaynorERDahlbergS. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med1993;328:10021006.

    • Search Google Scholar
    • Export Citation
  • 282

    CoiffierBLepageEBriereJ. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med2002;346:235242.

    • Search Google Scholar
    • Export Citation
  • 283

    FeugierPVan HoofASebbanC. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol2005;23:41174126.

    • Search Google Scholar
    • Export Citation
  • 284

    CoiffierBThieblemontCVan Den NesteE. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood2010;116:20402045.

    • Search Google Scholar
    • Export Citation
  • 285

    PfreundschuhMTrumperLOsterborgA. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol2006;7:379391.

    • Search Google Scholar
    • Export Citation
  • 286

    PfreundschuhMKuhntETrumperL. Randomised Intergroup trial of first line treatment for young low-risk patients (<61 years) with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab—6-year follow-up of the Mint Study of the Mabthera International Trial (MInT) Group [abstract]. Blood2010;116:Abstract 111.

    • Search Google Scholar
    • Export Citation
  • 287

    SonneveldPvan PuttenWHolteH. Intensified CHOP with rituximab for intermediate or high-risk Non-hodgkin’s lymphoma: interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma Groups [abstract]. Blood2005;106:Abstract 16.

    • Search Google Scholar
    • Export Citation
  • 288

    HabermannTMWellerEAMorrisonVA. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol2006;24:31213127.

    • Search Google Scholar
    • Export Citation
  • 289

    BlayneyDWLeBlancMLGroganT. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol2003;21:24662473.

    • Search Google Scholar
    • Export Citation
  • 290

    HalaasJLMoskowitzCHHorwitzS. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma2005;46:541547.

    • Search Google Scholar
    • Export Citation
  • 291

    PfreundschuhMTrumperLKloessM. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 292

    PfreundschuhMSchubertJZiepertM.